Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
filingDate |
2018-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_690dd3cdb98dce661f9d5b40fb4c4be7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c59d581a01ca8c6a01a5945e15682720 |
publicationDate |
2020-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3704137-A1 |
titleOfInvention |
Novel scaffolded hiv-1 vaccine immunogens |
abstract |
The present invention provides novel scaffolded HIV-1 vaccine immunogens. Some of the scaffolded immunogens contain a soluble gp140 trimer linked to the N-terminus of the nanoparticle subunit and a T-helper epitope that is fused via a short peptide spacer to the C-terminus of the nanoparticle subunit. Some other immunogens of the invention contain a soluble gpl40 trimer protein that is linked to a stable nanoparticle via a short peptide spacer that is a T-helper epitope. Some of the scaffolded immunogens contain a gp140 trimer immunogen presented on a nanoparticle platform formed with I3-01 protein, E2p, or variants of protein 1VLW. Also provided in the invention are nucleic acids that encode the various vaccine immunogens described herein, and expression vectors and host cells harboring the nucleic acids. The invention further provides methods of using the scaffolded HIV-1 vaccine immunogens for preventing or treating HIV infections. |
priorityDate |
2017-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |